# 1 The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins,

# 2 diversified for accessory proteins and stable long-term in children

- 3
- 4 Asmaa Hachim<sup>1</sup>, Haogao Gu<sup>2</sup>, Otared Kavian<sup>3</sup>, Mike YW Kwan<sup>4</sup>, Wai-hung Chan<sup>5</sup>, Yat

5 Sun Yau<sup>5</sup>, Susan S Chiu<sup>6</sup>, Owen TY Tsang<sup>7</sup>, David SC Hui<sup>8</sup>, Fionn Ma<sup>1</sup>, Eric HY Lau<sup>9</sup>,

- 6 Samuel MS Cheng<sup>2</sup>, Leo LM Poon<sup>1, 2</sup>, JS Malik Peiris<sup>1, 2</sup>, Sophie A Valkenburg<sup>1\*^</sup> and
- 7 Niloufar Kavian<sup>1, 10,11\*</sup>.
- 8

### 9 Affiliation

- 10 <sup>1</sup>HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of
- 11 Hong Kong, Hong Kong SAR, China.
- <sup>12</sup> <sup>2</sup>Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine,
- 13 The University of Hong Kong, Hong Kong SAR, China.
- <sup>14</sup> <sup>3</sup>Department of Mathematics, Université de Versailles Saint-Quentin, Versailles, France
- <sup>15</sup> <sup>4</sup>Department of Paediatric and Adolescent Medicine, Princess Margaret Hospital, Hospital Authority of Hong
- 16 Kong, Special Administrative Region of Hong Kong, China.
- 17 <sup>5</sup>Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special
- 18 Administrative Region of Hong Kong, China.
- <sup>19</sup> <sup>6</sup>Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary
- 20 Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, China.
- 21 <sup>7</sup>Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special
- 22 Administrative Region of Hong Kong, China.
- <sup>23</sup> <sup>8</sup>Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong,
- Hong Kong SAR, China.
- <sup>9</sup>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li
- 26 Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

- 27 <sup>10</sup>Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique–Hôpitaux de
- 28 Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d'Immunologie
- 29 Biologique, Paris, France.
- 30 <sup>11</sup>Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

31

- 32 \*Contributed equally to this study
- 33
- 34 ^corresponding author:
- 35 Sophie A Valkenburg
- 36 HKU Pasteur Research Pole
- 37 School of Public Health
- 38 The University of Hong Kong
- 39 sophiev@hku.hk
- 40
- 41 Short title: COVID-19 antibodies in children
- 42
- 43 Keywords: Antibody, COVID-19, asymptomatic, pediatric, IFN, accessory, structural,
- 44 longitudinal
- 45

# 46 Author contributions

- 47 A.H. and N.K. performed the experiments and analysed the data. H.G., O.K. and E.H.Y.L
- 48 performed specialist statistical analysis. M.Y.W.K, W.H.C, Y.S.Y, S.S.C, O.T.Y.T,
- 49 D.S.C.H and S.M.S.C provided clinical samples, which F.M processed. A.H., L.L.M.P.,

- 50 J.S.M.P., S.A.V. and N.K. designed the study, interpreted results and wrote the
- 51 manuscript.

## 53 Abstract

54 Background: Children are less clinically affected by SARS-CoV-2 infection than adults 55 with the majority of cases being mild or asymptomatic and the differences in infection 56 outcomes are poorly understood. The kinetics, magnitude and landscape of the antibody 57 response may impact the clinical severity and serological diagnosis of COVID-19. Thus, 58 a comprehensive investigation of the antibody landscape in children and adults is needed. 59 **Methods:** We tested 254 plasma from 122 children with symptomatic and asymptomatic 60 SARS-CoV-2 infections in Hong Kong up to 206 days post symptom onset, including 146 61 longitudinal samples from 58 children. Adult COVID-19 patients and pre-pandemic 62 controls were included for comparison. We assessed antibodies to a 14-wide panel of 63 SARS-CoV-2 structural and accessory proteins by Luciferase Immunoprecipitation 64 System (LIPS).

65 Findings: Children have lower levels of Spike and Nucleocapsid antibodies than adults, 66 and their cumulative humoral response is more expanded to accessory proteins (NSP1 67 and Open Reading Frames (ORFs)). Sensitive serology using the three N, ORF3b, ORF8 68 antibodies can discriminate COVID-19 in children. Principal component analysis revealed 69 distinct serological signatures in children and the highest contribution to variance were 70 responses to non-structural proteins ORF3b, NSP1, ORF7a and ORF8. Longitudinal 71 sampling revealed maintenance or increase of antibodies for at least 6 months, except 72 for ORF7b antibodies which showed decline. It was interesting to note that children have 73 higher antibody responses towards known IFN antagonists: ORF3b, ORF6 and ORF7a. 74 The diversified SARS-CoV-2 antibody response in children may be an important factor in 75 driving control of SARS-CoV-2 infection.

# 76 Introduction

77 The SARS-CoV-2 virus emerged in December 2019 and given the lack of pre-existing immunity has caused a pandemic. The spectrum of COVID-19 disease ranges from 78 79 asymptomatic to lethal infection. It is now evident that the immune response plays a major 80 role in the pathogenicity and outcome COVID-19<sup>1</sup>. Children are minimally affected 81 clinically by SARS-CoV-2 and the morbidity and mortality observed in adults increases 82 progressively with age, although the viral loads in the respiratory tract are reportedly 83 comparable between children of all ages and adults<sup>2</sup>. The multisystem inflammatory 84 syndrome (MIS-C) that appears in children after infection with SARS-CoV-2 is a rare 85 exception (0.002% of cases) to the generally milder clinical disease observed<sup>3</sup>. 86 Symptoms such as fever, cough, pneumonia and elevated C-reactive protein which are 87 associated with disease severity, are less common in children<sup>4</sup>. The majority of children 88 are asymptomatic and only a minority develop mild symptoms (most commonly fever, 89 cough, pharyngitis, gastrointestinal symptoms and anosmia)<sup>4</sup>, creating difficulties in 90 identifying pediatric cases and in contact tracing. These observations are in contrast with 91 other respiratory virus infections (respiratory syncytial virus (RSV), influenza virus) where 92 children are affected more commonly and more severely compared to adults<sup>5</sup>. Recently, 93 a small family case study by Tosif et al., indicated that children can mount an immune 94 response with detectable antibodies to SARS-CoV-2 without preceding detectable viral 95 load, therefore avoiding the development of a symptomatic SARS-CoV-2 infection<sup>6</sup>. The 96 clinical differences observed in children and adults upon SARS-CoV-2 infection may be 97 explained by several immune factors (amongst other clinical or physiological factors), 98 such as pre-existing and cross-reactive immunity to common cold coronaviruses  $(CCC)^7$ 

medRxiv preprint doi: https://doi.org/10.1101/2021.01.03.21249180; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

with more recent exposure likely in children, immuno-senescence and inflammatory
state<sup>8</sup>, innate immune responses, presence of auto-antibodies<sup>9</sup>, and "trained immunity"
as a result of off-target effects of live attenuated vaccines for other infections<sup>5,10</sup>.

102 Although a growing number of SARS-CoV-2 serology tests are currently in use worldwide 103 and are the basis of the SARS-CoV-2 infection rate data, there is an absence of 104 information on serological responses in children with RT-PCR confirmed SARS-CoV-2 105 infection. Large epidemiological studies report that children only represent 1-2% of all 106 SARS-CoV-2 cases<sup>11,12</sup> but this may be and underestimate because of differences in the 107 development of the antibody responses to SARS-CoV-2 in children and pandemic 108 response measures such as school closures. Serology is crucial for determining infection 109 attack rates in the population and for assessing the response to a future vaccine to curb 110 the global pandemic. Most serological tests available rely either on neutralizing antibodies 111 or on the detection of antibodies targeting the Spike (S) or the Nucleocapsid (N) proteins 112 of the virus<sup>13</sup>. We have previously demonstrated that antibodies that are directed against 113 non-structural proteins of the virus, namely ORF3b and ORF8, can be used for accurate 114 diagnosis of SARS-CoV-2 infection<sup>14</sup>. Whilst the cellular immune profile of children appears comparable to adults in a small case study<sup>6</sup>, there are no reports on the humoral 115 116 antibody landscape and kinetics in pediatric cases. There is a lack of information on the 117 SARS-CoV-2 antibody responses in adults or children to the virus accessory proteins, for 118 instance ORF3b, ORF6 and ORF7a, which have been reported to be potent interferon 119 antagonists that may play a role in immune evasion<sup>15-17</sup>. A finely tuned and balanced 120 antibody response may impact COVID-19 outcomes, and the breadth and magnitude of

the landscapes of antibody responses to non-structural proteins may indicate the extentof virus replication and thus immune control.

123 In the present study, children and adults with SARS-CoV-2 RT-PCR confirmed infection 124 were used to study the antibody landscape to a comprehensive panel of 14 different 125 structural and accessory proteins by LIPS. We tested a population of 122 infected children 126 and 36 infected adults in Hong Kong, including 58 patients with longitudinal samples (2) 127 to 4 time points, with a range 0 to 206 days post infection) to determine the longevity of 128 the antibody responses. Furthermore, due to intensive contact tracing and case-finding 129 measures in Hong Kong, asymptomatic cases with RT-PCR confirmed infections have 130 been identified and their antibody responses are also profiled. These samples were 131 collected between April to November 2020 and include predominantly the third wave of 132 infection cases in Hong Kong corresponding to the period of July to September 2020. Our 133 data reports to date, the most extensive data on the landscape and kinetics of antibody 134 responses in COVID-19 children.

#### 135 **Results**

# SARS-CoV-2 infected children have lower levels of antibodies than adults to all structural proteins, except E.

We used the unbiased and quantitative LIPS platform to determine the antibody titres to an extensive panel of 14 antigens from structural and non-structural SARS-CoV-2 proteins in plasma samples from a cohort of infected children, in comparison to adults and controls in Hong Kong (Table 1).

142 Our first data set represents COVID-19 cases of mixed timepoints and symptoms to 143 determine the overall antibody landscapes in children (mean+/-stdey: 39±47 days, range: 144 0-206 days), adults (mean±stdev: 54±20 days, range: 24-123 days) and negative 145 controls. S and N antibodies are the most widely used antibodies in COVID-19 serology 146 testing worldwide. We therefore first determined the levels of antibodies to different S 147 sub-units by using 3 different S constructs in the LIPS assay: S1 which contains the RBD domain, S2 and the S2' cleaved subunit (Figure 1). The levels of the two Spike antibodies, 148 149 S1 and S2' were markedly lower in children compared to the adult cohort (p<0.0001, 150 p=0.0015 and p<0.0001 respectively, Figure 1ac), whereas no difference was observed 151 for S2 antibodies (Figure 1b). Moreover, N antibodies were significantly elevated in the 152 pediatric COVID-19 cohort relative to negative controls (2.45e5±2.8e5 LU versus 153 4.15e4±1.5e4 LU (p=0.0045), but did not reach the levels observed in the COVID-19 adult cohort that were almost half a log above (5.45e5±3.0e5 LU adult COVID-19 cohorts, 154 155 p<0.0001, Figure 1d).

We also assessed by LIPS antibodies to other structural proteins Matrix (M) and Envelope(E), which are not widely measured in serology. As for S1, S2', and N, we found that M

antibody levels were lower in the COVID-19 children compared to the adult COVID cohort
(p<0.0001, Figure 1e) but were significantly higher that seen in controls. E antibodies</li>
followed an inversed trend as they were significantly elevated in the pediatric COVID-19
cohort (Figure 1f) compared to both adult COVID-19 (p=0.0006) and negative controls
(p<0.0001).</li>

163

Increased breadth of accessory antigen targets in the pediatric COVID-19
 population.

166 We next investigated the levels of antibodies directed against the non-structural protein 1 (NSP1) and all the ORFs proteins of the virus. In line with our previous study<sup>14</sup>, adults 167 168 with COVID-19 displayed elevated levels of NSP1, ORF3a, ORF3b, ORF7a, ORF7b, and 169 ORF8 antibodies compared to negative controls (p<0.0001, p<0.0001, p<0.0001, p=0.05, 170 p=0.0009, p<0.0001, Figure 2a-c and e-g). Again, no detectable levels of ORF6 and 171 ORF10 antibodies were detected in the adult COVID-19 population (p=0.8691 and 172 p=0.999 respectively, Figure 2d and 2h). We observed that the COVID-19 children cohort 173 displayed significantly lower levels of ORF3a, ORF7a, ORF7b antibodies than the adult 174 COVID-19 cohort (p=0.0001, p<0.0001 and p<0.0001 respectively, Figure 2b, e-f). The 175 magnitude of antibody responses to NSP1, ORF3b and ORF8 were comparable in the 176 pediatric COVID-19 and adult COVID-19 populations, and significantly elevated 177 compared to negative controls (Figure 2c and g).

Cumulative SARS-CoV-2 antibody responses from COVID-19 children and adults populations were then compared as percentages of the total SARS-CoV-2 structural and accessory antibody response. The anti-N antibodies substantially dominate the SARS-

181 CoV-2 humoral response detected by LIPS in both populations (Figure 2i-j), which is 182 consistent with our previous findings in the adult population<sup>14</sup>. Due to the 183 immunodominant effect of anti-N antibodies, we also performed analysis with or without 184 N, both of which were highly significant (p<0.0001 Supplemental Figure 1b-e). 185 Furthermore, representation of cumulative percentages of single specific antibodies to 186 the global SARS-CoV-2 antibody response shows that the amount of the response 187 towards the accessory proteins (NSP1 and ORFs) is increased over the response 188 towards the structural ones in the pediatric COVID-19 population versus the adult COVID-189 19 population (8.81% versus 4.36% for the response to accessory proteins, p=0.019, Figure 2i) despite no significant differences in total IgG levels in both populations 190 191 (Supplemental Figure 1a).

192

# Deciphering the SARS-CoV-2 antibody landscape differences in children and adults using clusters of points and principal component analysis.

A cluster of points depicts each individual sample in a more complete way than a single statistical comparison, as it considers a combination of three (or more) different parameters taken together and the relevant relations of these parameters. To decipher the SARS-CoV-2 antibody landscape in children, we used relevant antibody combinations to represent the COVID-19 pediatric samples in clusters of points along with the negative and COVID-19 adult populations (Figure 3a-c and Supplemental figure 20.

202 First, the cluster representing the three antibodies to the S subunit antigens S1, S2', S2 203 confirmed that the pediatric population has a S antibody profile that is more closely 204 comparable to negative controls (Figure 3a) than an adult COVID-19 response by LIPS 205 (Figure 3b). Further cluster analysis of antibodies to S1, S2' with N, or other structural 206 proteins N, M, and E reveals that the COVID-19 children population appears to be quite 207 heterogeneous (Supplemental Figure 2a-b). Despite having a different profile than both 208 the adult COVID-19 and the negative populations, the pediatric population cannot be 209 clearly discriminated.

210 We then selected accessory protein antibodies as combinations to investigate the 211 relevance of under-utilized markers. ORF3b and ORF8 antibodies were selected, along 212 with N antibodies, as both were previously shown to discriminate accurately COVID-19 adults from negative controls<sup>14</sup>. The (N, ORF3b, ORF8) cluster of points can accurately 213 214 allow the positive discrimination of the pediatric COVID-19 cases from the negatives 215 (Figure 3c). Indeed, in the (N, ORF8; x, y) plane, the negative population is separated 216 from the adult and pediatric positive ones by two-segments of straight lines (equations of 217 830\*log (N) +0.3843\*ORF8=4801 and -350\*log (N) +1.036\*ORF8=790, with all positive 218 samples represented above or on these lines, and only one negative sample being above 219 these lines). Then, using the (ORF3b, ORF8; y, z) plane, again, two-segments of straight 220 0.035\*ORF3n+0.1334\*ORF8=409.284 lines (equations of and 221 0.074\*ORF3b+0.0437\*ORF8=221.812) separate the negative samples from the adult 222 and pediatric positive ones. Therefore, the (N, ORF3b, ORF8) cluster reveals that the pediatric COVID population resembles a COVID-19 adult population and can be 223 224 discriminated from negative pre-pandemic controls. Importantly, this is the only

225 combination that allowed us this discrimination, as other parameter combinations (e.g. 226 (N, S1, S2'), (N, E, M) in Supplemental Figure 2) and combinations of antibodies to 227 accessory proteins) were also tested and represented as clusters of points but did not 228 discriminate pediatric samples. These data cluster analysis show that the antibody 229 landscape of the COVID-19 children population is distinct from the adult one.

230 To test the hypothesis that the antibody landscape to structural and accessory viral 231 proteins drives the distinct profile of the pediatric population, we undertook a principal-232 component analysis (PCA) of the 14 SARS-CoV-2 antibodies for the full data set (from 233 Figure 1 and 2). Dimension (principal component) 1 and 2 explained respectively 21% 234 and 15% of the total variances from all the 14 antibody types (Figure 3d-e). Accessory 235 proteins ORF3b, NSP1, ORF8, ORF3a, ORF7a, ORF6 and ORF10 had high correlation 236 values (Supplemental table 1), reflecting that antibodies to structural proteins do not 237 solely drive the principal component 1. Particularly, contributions of ORF3b, NSP1, ORF8, 238 ORF3a were the highest in Dimension 1 (Dim1, Figure 3de). Moreover, PCA showed that 239 ORF3b and ORF7a antibodies highly contributed to the differences seen in both 240 dimensions (Figure 3d) highlighting their importance in the serological response.

Strikingly, the PCA revealed that pediatirc COVID-19 antibody response was also intermediate between COVID-19 adults and negatives (Figure 3f). Indeed, the normalprobability representation of the 3 populations showed that only 18.9% of the pediatric patients overlapped with the ellipse of the COVID-19 adults and only 3.54% overlapped with the ellipse of the negatives (Figure 3f). Further analysis on gender, time-point, symptoms and neutralization data (PRNT90) values reported that these were not

significant factors in discriminating the data (Supplemental Figure 3). Therefore, the differences in the observed SARS-CoV-2 antibody responses is primarily explained by the age and type of patients: pediatric COVID-19, adult COVID-19 or pre-pandemic negative controls.

251

# No difference in antibody responses between symptomatic and asymptomaticCOVID-19

254 To assess the potential effect of antibodies to structural and non-structural proteins of 255 SARS-CoV-2, we further stratified data (from Figure 1 and 2) into symptomatic 256 (mild/severe) and asymptomatic for both the adult and pediatric cohorts. 257 We found no differences in antibody responses between asymptomatic and mild COVID-258 19 children for all 14 antigens. In adults, we observed the same trend excluding ORF3a 259 antibody levels which are higher for symptomatic patients (p=0.0403, Figure 4b). More 260 importantly N, M, ORF3a and ORF7b antibody levels in asymptomatic children versus 261 asymptomatic adults were not significantly different (p=0.5673, p=0.2669, p=0.9185 and 262 p=0.0859 respectively, Figure 4), whilst symptomatic adults had an upregulated antibody 263 response to these antigens compared to symptomatic children (p<0.0001 for all 4 264 antigens, Figure 4 and Supplemental Figure 4a).

265

### 266 Antibody landscapes at early infection and long-term stability

267 We previously observed that the SARS-CoV-2 antibody responses can vary in magnitude 268 and specificity in adults between acute and convalescent to memory time-points<sup>14</sup>. To

study the effect of time in the pediatric COVID-19 population, we stratified pediatric responses of all 254 samples (Figures 1 and 2) by early (<d14) versus later (≥d14) timepoints (Figure 5). S2, N and ORF7a specific antibodies were significantly increased after day 14 post symptom onset. In contrast, ORF3b and ORF7b antibodies elicited a higher antibody response prior to day 14 (Figure 5b). Finally, responses to structural proteins S1, S2, M and E and accessory proteins NSP1, ORF3a, ORF6 and ORF8 were comparable before and after day 14 (Figure 5ab).

To further confirm the stability of SARS-CoV-2 specific antibodies we used 146 276 277 longitudinal paired samples of 58 pediatric patients that had either 2, 3 or 4 blood draws 278 (Figure 6a). The time-frame of sampling ranged from 0 to 206 days post-symptom onset. 279 with the majority of samples from <14 days (n=63), or long term memory samples after 280 day 60 (n=58) (Figure 6b). Using a linear mixed effects model, we determined that 281 antibody responses to structural proteins S1, S2, S2', M and E were stable over time, 282 whereas N was significantly increased (p<0.001) (Figure 6c). Furthermore, antibodies 283 towards non-structural proteins NSP1, ORF3a, ORF3b and ORF7a also significantly 284 increased over time (p<0.001, p=0.001, p=0.027 and p=0.002 respectively), whilst ORF6, 285 ORF8 and ORF10 were stable (Figure 6c). Only ORF7b antibody response significantly 286 decayed longitudinally at a slow rate (p<0.001, Figure 6c). In order to determine whether 287 the slope of each serological marker could inform the disease outcome we compared 288 asymptomatic and symptomatic patients but no significant differences were found (p>0.05 289 for all) (Supplemental figure 4).

290

292

#### **A distinct antibody landscape may impact IFN**α levels

294 Severe COVID-19 disease is associated with low IFN $\alpha$  responses in adults which has been linked to the type-I IFN down-regulation roles of ORF3b. ORF7a and ORF6<sup>15-17</sup>. 295 296 Antibodies to these 3 proteins in a cluster of points (ORF3b, ORF7a, ORF6 as x,y,z), 297 show that children have a heterogenous humoral profile towards these 3 type-I IFN down-298 regulators (Figure 7a). To assess the IFN $\alpha$  response a guantitative ELISA was conducted 299 on plasmas collected before day 7 in children (n=48) and adults (n=18) (Figure 7b). We 300 observed a significant decrease of acute IFN $\alpha$  levels in children compared to the adult 301 samples (p=0.0165, Figure 7b), with only 3 pediatric samples showing a detectable IFN $\alpha$ 302 level. To further investigate the antibody profiles with IFN $\alpha$  responses, the total antibody 303 response of these 3 IFN $\alpha$  producing children compared to the non-responder children 304 (n=45), we plotted the average antibody responses to all 14 antigens for each group (Pediatric IFN $\alpha^{-}$  versus Pediatric IFN $\alpha^{+}$ , average: Figure 7c, and individuals: 305 306 Supplemental figure 6). We found a significant difference in the antibody distribution in 307 the 3 IFN $\alpha$  producing children versus the IFN $\alpha$  non-producing children (IFN $\alpha^+$  versus 308 IFN $\alpha^{-}$ , p<0.0001), with IFN $\alpha^{+}$  children having increased ORF6, ORF7a and ORF3b antibodies, and lower ORF8 and E antibody levels. Notably ORF6 antibody levels were 309 310 particularly higher in one IFN $\alpha^+$  asymptomatic child with low viral loads (Figure 7d).

# 312 Discussion

Young children account for only a small percentage of reported and medically attended COVID-19 infections<sup>5</sup>, which is unlikely to be completely explained by reduced exposures and school closures. This difference is likely contributed to by differences in host responses between children and adults. We present herein the most comprehensive study to date of the magnitude, specificity and duration of SARS-CoV-2 specific antibodies in children.

319 While the understanding of immunity to COVID-19 is growing at a fast pace, 320 information on the pediatric population remains limited largely due to their asymptomatic and mild illness compared to the adult population. Furthering our understanding of the 321 322 immune mechanisms that lead to this mild clinical presentation could represent new 323 alternative therapeutics, prevention methods or improved diagnostics. Our work enables 324 unique serological insights on the long-term response and asymptomatic infections as 325 Hong Kong's pandemic control strategy has intensive testing, contact tracing and isolation 326 of all COVID-19 cases including asymptomatic and mild cases with longitudinal follow up. 327 This has provided us the opportunity to investigate a cohort of children with both 328 symptomatic and asymptomatic children. We describe the antibody diversity between day 329 0 and day 206 post-symptom onset, and reveal major differences in the antigens targeted 330 by the humoral immune response of COVID-19 children compared to adults which may 331 indicate differences in viral protein propagation kinetics, pathogenesis and IFN immune 332 evasion.

Importantly, we report that the proportion of the antibody response targeting theaccessory proteins is significantly increased in children versus adults. Antibodies to the

335 N structural protein largely dominate the humoral immune response both in children and 336 adults, though the total magnitude of the N-specific antibodies in children is substantially 337 lower than adults. Visualization of N antibody levels in our cluster representations clearly 338 show that only half of the pediatric cases have comparable levels of these antibodies to 339 adults. Others have also reported a reduced magnitude of N antibodies in children and 340 they suggested that this observation could be related to a lower release of N proteins 341 related to lower replication in children<sup>18</sup>. On the contrary, our data show that children 342 produce antibodies to some accessory proteins (namely NSP1, ORF3b and ORF8) at 343 similar levels to adults, and to structural protein E in higher proportions than adults, the latter notorious for high turnover due to its pivotal role in viral propagation (reviewed in<sup>19</sup>). 344 345 Therefore, these accessory proteins are not being released to a lesser extent in children 346 but may reflect different virus pathogenesis in children compared to adults. Viral loads 347 have been shown to be comparable in children and adults, which may reflect similar levels 348 of viral replication<sup>2</sup>.

349 For the Spike subunits antibodies, the (S1, S2', S2) cluster reveals that the children 350 population resembles a negative pre-pandemic population and not a COVID-19 adult one. 351 A recent study describes a lower anti-S IgG, IgM, IgA in the pediatric population which 352 correlates with our findings <sup>20</sup>. One explanation on the clinical difference between children 353 and adults raise that the pre-existing immunity against seasonal human coronaviruses 354 (HCoVs) that cross-reacts with SARS-CoV-2 is higher in children, as they have a higher infection rate of seasonal HCoVs than adults<sup>21</sup>. Individuals exposed and unexposed to 355 356 SARS-CoV-2 have cross-reactive antibodies against the proteins of SARS-CoV-2 and 357 seasonal HCoVs<sup>22,23</sup>. Moreover because circulating HCoVs have a higher homology to

SARS-CoV-2 structural proteins than non-structural proteins (if they exist)<sup>24,25</sup>, we would expect a higher cross-reactivity for structural proteins based on pre-existing immunity. SARS-CoV-2 infection back-boosts antibodies against conserved epitopes, including the relatively conserved fusion peptide of the Spike S2 subunit<sup>22,23</sup>. In our hands, COVID-19 children and adults had comparable levels of S2 antibodies, contrary to S1 and S2', which shows a possible effect of pre-existing HCoVs immunity for more conserved domains of S such as S2.

365 Our observations of lower Nucleocapsid and Spike antibodies in COVID-19 children may 366 indicate that there may be lower sensitivity of serological detection for SARS-CoV-2 when 367 using assays based on S and/or N alone, leading to an underestimation of SARS-CoV-2 368 exposed children. S antibodies have been reported in lower magnitude in the majority of 369 mild adult infections, with higher levels being produced in severe cases<sup>26</sup>, which is 370 consistent with our data on low S antibody levels in children which were also 371 asymptomatic or mild clinical scores. Low antibody levels and low affinity have been 372 associated with Antibody Dependent Enhancement by facilitation of viral uptake by host 373 cells<sup>27</sup>, however yet no definitive evidence of ADE for SARS-CoV-2 neither in adults nor 374 in children has been brought forward<sup>28</sup>, but warrants further investigation.

The plane (ORF3b/ORF8) in the cluster of points (N, ORF3b, ORF8) reveals that children samples have specific combinatory values of these two antibodies that is consistent with adult populations, and that makes them distinguishable from the negatives. Similar to NSP1, we report the proportion of all non-structural antibodies makes a greater contribution of the SARS-CoV-2 response in children than in adults. The Principal Component Analysis of our dataset confirmed further the importance of antibodies to

accessory proteins in characterising the pediatric samples. Whether these antibodies to accessory proteins play a role in the virus infectivity or in the pathogenesis of the disease and in the milder outcome of SARS-CoV-2 infection in children presents further questions for investigations.

385 ORF3b, ORF7a and ORF6 proteins have been previously reported to play a role in cellular 386 type-1 IFN down-regulation<sup>15-17</sup>. The cluster representation of ORF3b, ORF7a and ORF6 387 antibodies shows a different pattern between adult and children population. Furthermore, 388 the PCA revealed that ORF7a and ORF3b contributed highly to component 1 and 2 (Dim1 389 and Dim2) which accounted for 21% and 15% of the variances observed respectively, 390 pointing to a potential pivotal role of these antigens. In all COVID-19 infected children or 391 adults tested at early timepoints of infection (< day 7), the majority did not elicit a detectable IFN $\alpha$  response, in line with previous findings<sup>30</sup>, but overall children IFN $\alpha$ 392 393 responses were significantly lower than the adult ones. Amongst the IFNa responders 394 and non-responders in children a different antibody landscape suggests possible 395 functions of these markers in counteracting viral IFN down-regulation, with ORF6 396 antibody responses doubled in IFNa<sup>+</sup> children. Bastard et al., reported anti-type I 397 interferon auto-antibodies in a subset of severe COVID-19 patients<sup>9</sup>. Moreover, a recent 398 study has linked high levels of auto-immunity with COVID-19 severe cases in adults<sup>31</sup>. As 399 children are less predisposed to auto-immunity than adults<sup>32</sup>, it is possible this contributes 400 to their milder clinical presentation along with the diversified antibody landscape observed 401 in our study.

402 We report in children diverse antibody profiles in early versus late samples and the 403 maintenance or increase of all antibodies to structural and accessory proteins, except

404 ORF7b antibodies, for at least 6 months post-infection. Many factors play a role in 405 antibody long-term persistence, such as antigen release, antigen presentation, induction 406 of a germinal centre reaction and a memory B cell pool<sup>33</sup>. Additional studies on viral 407 proteins release, their roles and their specific B cells are needed to fully understand the 408 antibody landscape in children.

409 Our cohort did not include any case of Multi-inflammatory System in Children (MIS-C). 410 Although one study reported that no distinct antibody response was observed between 411 MIS-C and mild or asymptomatic children<sup>18</sup>, it only measured S and N antibodies. 412 Therefore it would be of interest to study the whole spectrum of antibodies in this 413 population and particularly those targeting accessory proteins. In our hands, symptomatic 414 children have significant differences in antibody levels versus symptomatic adults only for 415 selected antibodies (N, M, ORF3a and ORF7b) which suggests that these markers could 416 play a role in infection control or infectivity.

417 It is possible that the interest for antibodies to SARS-CoV-2 internal proteins will grow 418 with the rollout of sub-unit Spike only vaccines, in order to allow the distinction between 419 SARS-CoV-2 past exposure and vaccination in specific populations and to create an 420 estimated date of exposure given the unique rate of waning of different specificities. The 421 emergence of certain viral mutants such as the ORF8 truncations<sup>34</sup> or recent ORF3b deletions<sup>35</sup> could modify the contributions of certain ORFs, their antibodies responses 422 423 could also be used for epidemiology studies on the insurgence of different strains of the 424 virus.

In conclusion, we report the description of a more diversified antibody landscape
 in the COVID-19 children population compared to adults, with an increased and sustained

- 427 humoral response to all accessory proteins of the virus. This study of antibody spectrum
- 428 provides insights into the importance of the breadth of responses and how it differs
- 429 between children and adult that have diverse outcomes of infection, and could inform
- 430 improved SARS-CoV-2 diagnostics for the pediatric population.

# 431 Methods

#### 432 **Patients and samples collection**

433 Our study enrolled a total of 122 children patients and 36 adult patients based on 434 recruitment of available patients with RT-PCR confirmed COVID-19 infection in Hong 435 Kong. We used a total of 254 COVID-19 children plasma samples including 146 436 longitudinal samples from 58 subjects with 2 to 4 sampling time points, and 119 early 437 time-points samples (< day 14). Samples were used from children (mean±stdev: 39±47 438 days, range: 0-206 days) and adults (mean±stdev: 54±20 days, range: 24-123 days), with 439 the sample day was defined as day post-symptom onset or RT-PCR confirmation for 440 asymptomatic cases through contact tracing or guarantine. For measurement of IFN $\alpha$ , an 441 extra set of 18 COVID-19 adult patients sampled prior to day 7 was used in comparison 442 to 48 samples that were collected prior to day 7 in the COVID-19 pediatric cohort. The 443 COVID-19 patient study was approved by the institutional review board of the respective 444 hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon Central / 445 Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW 446 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories East Cluster 447 Clinical Research Ethics Committee (CREC 2020.229). All of patients provided informed consent. 448

The negative control plasma samples used in this study were from Hong Kong blood donors collected from June to August 2017 (prior to the emergence of COVID-19), used a total of 33 plasma samples including negative pediatric samples (n=20) and negative adult samples (n=13). The collection of negative control blood donors was approved by the Institutional Review Board of The Hong Kong University and the Hong

Kong Island West Cluster of Hospitals (approval number: UW16-254). Plasma samples
were collected from heparinized blood. All samples from COVID-19 patients or negative
controls were heat-inactivated prior to experimental use at 56°C for 30 minutes. Details
on the sample cohort are presented in Table 1.

458

# 459 SARS-CoV-2 cloning and (Ruc)-antigen expression

Based on previous studies describing the structure of the SARS-CoV-2 genome<sup>25,36</sup>, an extensive panel of 14 proteins (S1, S2, S2', E, M, N, NSP1, ORF3a, 3b, 6, 7a, 7b, 8, 10) was chosen for antibody testing by LIPS. Primers and cloning for the amplification of SARS-CoV-2 proteins were as previously described<sup>14</sup>. Constructs with pREN2-Renilla luciferase plasmid containing the SARS-CoV-2 antigen of interest were transfected into Cos1 cells and prepared as previously described<sup>14</sup>.

466

## 467 Measurement of antibody responses using LIPS

468 The LIPS assays were performed following the protocol of Burbelo et al., with the following 469 modifications<sup>36</sup>, as previously described<sup>14</sup>. Briefly, (Ruc)-antigen (at an equal 470 concentration for each antigen at 10<sup>7</sup> per well) and plasma (heat inactivated and diluted 471 1:100) were incubated for 2 hours with shaking at 800rpm. Ultralink protein A/G beads 472 (Thermo-Fisher) were added to the (Ruc)-antigen and serum mixture in a 96-deep-well 473 polypropylene microtiter plate and incubated for 2 hours with shaking at 800rpm. The 474 entire volume was then transferred into HTS plates (Millipore) and washed as previously 475 described. The plate was read using QUANTI-Luc Gold substrate (Invivogen) as per 476 manufacturer's instructions on a Wallac MicroBeta JET luminometer 1450 LSC &

Luminescence counter and its software for analysis (PerkinElmer). Experimental controls include no plasma blank wells with (Ruc)-antigens and negative control serum from healthy donors plasma collected prior to the COVID-19 pandemic. The background corresponds to the LU signal from each Ruc-fusion antigen with protein A/G and substrate with no plasma.

482

#### 483 Enzyme-linked immunosorbent assay

Total IgG were measured in plasma samples using the Total human IgG ELISA kit (Thermo-Fisher) at a final dilution of 1:500,000 according to manufacturer's instructions. IFN- $\alpha$  was measured in plasma samples using the Human IFN- $\alpha$  Platinum ELISA kit (Invitrogen) at a dilution of 1:5 according to manufacturer's instructions.

488

#### 489 **Clusters of points**

The SARS-CoV-2 antibodies dataset has been treated through the free software ConTeXt, with LuaMetaTeXengine (version 2020.05.18) developed by Hans Hagen (<u>http://www.pragma-ade.nl</u>) which uses TeX, Metapost and Lua to obtain the 3D clusters of points shown in Figure 3abc, Figure 7c and Supplemental Figure 2. For clarity, only the first 144 COVID-19 pediatric samples of the dataset are represented in the clusters of points, along with n=36 COVID-19 adult samples and n=28 negatives. In the cluster (N, ORF3b, ORF8), the equations of the red lines are: (1) in the plane (N,

497 ORF8) :830\*log (N) +0.3843\*ORF8=4801 and -350\*log (N) +1.036\*ORF8=790, and (2) 498 in the plane (ORF3b, ORF8): 0.035\*ORF3b+0.1334\*ORF8=409.284 and

499 0.074\*ORF3b+0.0437\*ORF8=221.812. These straight lines allow the most accurate
500 discrimination between negative controls and positive adult populations.

501

#### 502 **Principal component analysis**

The LU for 14 antigens were log-scale transformed (the negative and zero values in the data set were replaced by 1) prior to PCA analysis. The missing values in the dataset were estimated by a probabilistic model <sup>37</sup>. The probabilistic model is tolerant to amounts of missing values between 10% to 15% which is fit for our data. The missing data was estimated using pcaMethods (version 1.80.0)<sup>38</sup>. The completed data were standardized (scaled) before input in standard PCA (using *FactoMineR* (version 2.4)<sup>39</sup>.. The PCA results were extracted and visualized using factoextra (version 1.0.7)<sup>40</sup>.

510

#### 511 Statistics and Reproducibility

512 GraphPad Prism version 8 software (San Diego, CA) was used for statistical analysis. All 513 experiments were repeated twice independently. Antibody levels are presented as the 514 individual responses and geometric mean +/- standard deviation (stdev). Ordinary one-515 way ANOVA with Tukey's multiple comparison test were performed to compare the 516 pediatric, adult and negative populations in Figures 1 and 2, and the early and late 517 samples in Figure 5. For Figure 2j, percentages were calculated by dividing each mean 518 antibody value by the sum of the total antibody responses, and compared using a Chi-519 square test between the "observed" (pediatric) versus "expected" (adult) distributions. For Figure 6c and Supplementary figure 3, a linear mixed effects model was fitted to 520

521 account for correlated responses for the longitudinal samples dataset. Log<sub>10</sub> LIPS was

- 522 used for the analysis (as dependent variable) to reduce the impact of extreme values/non-
- 523 normality. For Supplementary figure 1, the distributions showed in the pie-charts were
- 524 compared using a Chi-square test between the "observed" (pediatric) versus "expected"
- 525 (adult) distributions.
- 526

# 527 Data availability statement

- 528 The data that support the findings of this study are available from the corresponding
- 529 author upon request.
- 530

# 531 Figure legends

532 Figure 1. Comparison of antibody responses to SARS-CoV-2 structural proteins in 533 children and in adults with COVID-19. Antibodies against the SARS-CoV-2 structural 534 proteins Spike S1 subunit (S1) (a), Spike S2 subunit (b), Spike S2' subunit (c), 535 Nucleocapsid (N) (d), Membrane (M) (e), and Envelope (E) (f) were measured by LIPS 536 from samples from pediatrics COVID-19 (n=254) or adult patients (n=36), and negative 537 controls (n=33). Background no plasma values were subtracted. Experiments were 538 repeated twice. All data represents individual responses, and the mean +/- stdev. Two-539 sided P values were calculated using the Mann-Whitney U test. \* shows statistical 540 significance between COVID-19 patients versus negative controls. \*\*p<0.01, \*\*\*p<0.001, 541 \*\*\*\* p<0.0001.

542

543 Figure 2. Antibody responses to SARS-CoV-2 non-structural proteins and ORFs are 544 lower in magnitude in children than in adults with COVID-19 but represent globally 545 a higher proportion of the SARS-CoV-2 humoral response. Antibodies against NSP1 546 (a) (in ORF1ab), and other ORFs (ORF3a (b), ORF3b (c), ORF6 (d), ORF7a (e), ORF7b 547 (f), ORF8 (g) and ORF10 (h)) were measured in pediatric (n=254) and adult (n=36) 548 COVID-19 cases and negative controls (n=33) by LIPS to cover all the ORFs of the virus. 549 (i) A heatmap comparing the mean titres (LU) for structural (N, S, S1, S2', S2, M, E) and 550 accessory proteins (NSP1, ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF10) responses 551 in the COVID-19 pediatric and adult populations and Negatives. (j) Percentages of single 552 antibody levels to SARS-CoV-2 antigens of the cumulative SARS-COV-2 antibody 553 response in COVID-19 children and adults for the 14 antigens. Experiments were repeated twice. Two-sided P values were calculated using the Mann-Whitney U test. \* shows statistical significance between COVID-19 patients versus negative controls. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\* p<0,0001. Data in (a-h) represents the individual responses and mean +/- stdev, data in (i) represents mean values (LU), data in (j) represents percentages.

559

560 Figure 3. Representation of the pediatric COVID-19 population as a cluster of points 561 for relevant antibody combinations and Principal Component Analysis (PCA). (a-562 b). Cluster representation of S1, S2', S2 antibodies combination. (a) shows the pediatric 563 COVID-19 population versus the adult COVID-19 population. (b) shows the pediatric 564 COVID-19 population versus the negative population. (c) Cluster representation of N, 565 ORF3b, ORF8 antibodies combination, for the pediatric COVID-19 population versus the 566 adult COVID-19 population and the negative population. Patients are presented 567 according to their values of SARS-CoV-2 individual LIPS antibodies as (x, y, z) in the 568 space. Pediatric COVID-19 patients (n=144) are represented as red dots. COVID-19 adult 569 patients (n=36 in (a-b) and n=24 in (c)) are represented in blue. The negative population 570 (n=28) is represented in gray. (d-f) PCA of 14 antibodies analyzed in COVID-19 pediatric 571 patients. Dim1 explains 21% of the variation, while Dim2 explains 15% of the variation. 572 (d) Correlation circle and contributions. The scale of contributions is indicated (right). (e) 573 Contribution of variables on dimensions 1 and 2. The red dashed line on the graph above 574 indicates the expected average contribution. (f) Factorial plot of PCA on dimension 1 and 575 2. The plot is colored by sample types, the largest point in shape in each group is the

576 group mean point (circle is for Adult positives, triangle for Negatives and squares for577 Pediatric positives).

578

579 Figure 4. Asymptomatic and mildly symptomatic children do not display different 580 antibody landscapes. Pediatric and adult samples were stratified according to the 581 symptom score of the patients (asymptomatic « asympto » (pediatric COVID-19 n=98, 582 adults COVID-19 n=9) versus symptomatic « sympto » (pediatric COVID-19 n=156, 583 adults COVID n=27)), data from Figure 1 and 2 were analyzed according to "asympto" 584 and "sympto". (a) Antibodies against the SARS-CoV-2 structural proteins S1, S2, S2', N, 585 E, and M by LIPS. (b) Antibodies against SARS-COV-2 NSP1 (in ORF1ab), and all other 586 ORFs (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8 and ORF10). Two-sided P values 587 were calculated using the Mann-Whitney U test. \* shows statistical significance between 588 COVID-19 patients versus negative controls. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\* p<0,0001. All data represent individual responses and the mean +/- stdev. 589

590

591 Figure 5. A unique antibody landscape is specific of early time-point samples (< 592 day 14). Pediatric samples were stratified according to the time-point of collection, and 593 data from Figure 1 and 2 were analyzed according to acute (<day 14, n=119) and later 594 time-points (>day 14, n=135). (a) Antibodies against the SARS-CoV-2 structural proteins 595 S1, S2, S2', N, E, and M by LIPS. (b) Antibodies against NSP1 (in ORF1ab), and all other 596 ORFs (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8 and ORF10). P values were 597 calculated using the student t test. \* shows statistical significance between acute time-598 point pediatric COVID-19 patients versus late time-point pediatric COVID-19 patients.

599 \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\* p<0,0001. All data represent individual responses and</li>
 600 the mean +/- stdev.

601

Figure 6. Longitudinal stability of antibody responses for structural and nonstructural SARS-CoV-2 proteins in COVID-19 children. (a) Number of longitudinal patients with either 2, 3 or 4 blood draws from 58 pediatric COVID-19 cases. (b) Sample collection time-line (days post infection). (c) A linear trend on log<sub>10</sub> LIPS values was fitted for longitudinal samples for S1, S2', N, M E, NSP1, ORF3a, ORF3b, ORF7a, ORF7b, ORF8 (n=58 pediatric COVID-19 patients).

608

609 Figure 7. IFN- $\alpha$  producing pediatric patients display a different landscape of 610 antibody response to SARS-CoV-2 accessory proteins. (a) Cluster representation of 611 antibodies to the accessory proteins ORF3b, ORF7a, ORF6 (x, y, z) for the COVID-19 612 pediatric samples (red, n= 144) versus the COVID-19 adult samples (blue, n= 27). (b) 613 Plasma IFN- $\alpha$  concentrations (pg/ml) in pediatric (n=48) and adult COVID-19 cases 614 (n=18) early timepoint samples (< day 7). Data represents individual responses and the 615 mean +/- stdev. (c) Pie charts of the cumulative antibody responses to the relevant SARS-616 CoV-2 structural and non-structural protein antigens (excluding N) in COVID-19 pediatric cohort stratified (positive/negative) by their IFN-α responses. (d) Individual data for IFN-617 618  $\alpha^+$  pediatric cases viral loads by RT-PCR, ORF3, ORF6, and ORF7b LIPS LU. P values 619 were calculated using Chi-squared test between the mean of IFN $\alpha$ - pediatric COVID-19 620 patients (N=45) and the IFNα<sup>+</sup> (N=3). ns, p=0.0591 \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\* 621 p<0.0001.

# 622 Acknowledgements

The authors thank the patients and their families for their participation, and are grateful to the hospital staff, clinicians and nurses, particularly Karen YS Yui, for sample coordination. We thank Professor JT Wu, Dr Mahen RP Perera and Dr Kathy Leung for providing donor plasma controls. This study was partly supported by the Theme based Research Grants Scheme (T11-712/19-N), Health and Medical Research Fund (HMRF COVID-190115 and COVID-190126), National Institutes of Allergy and Infectious Diseases, National Institutes of Health (USA) (contract HHSN272201400006C).

630

#### 631 Ethics declaration

632 The COVID-19 patient study was approved by the institutional review board of the 633 respective hospitals, viz. Kowloon West Cluster (KW/EX-20-039 (144-27)), Kowloon 634 Central / Kowloon East cluster (KC/KE-20-0154/ER2) and HKU/HA Hong Kong West Cluster (UW 20-273, UW20-169), Joint Chinese University of Hong Kong-New Territories 635 East Cluster Clinical Research Ethics Committee (CREC 2020.229). All of patients 636 637 provided informed consent. The collection of plasma from blood donors serving as 638 controls was approved by Institutional Review Board of The Hong Kong University and 639 the Hong Kong Island West Cluster (UW16-254).

640

#### 641 **Competing interests**

A Hachim, N Kavian, LLM Poon, JSM Peiris and SA Valkenburg have filed an IDF (US
63/016,898) for the use of ORF8 and ORF3b as diagnostics of SARS-CoV-2 infection.

644

# 645 **References**

- Vabret, N., *et al.* Immunology of COVID-19: Current State of the Science. *Immunity*52, 910-941 (2020).
- Jones T.C., M.B., Veith T., Guido Biele, Marta Zuchowski, Jörg Hoffmann, Angela
  Stein, Anke Edelmann, Victor Max Corman, Christian Drosten. An analysis of
  SARS-CoV-2 viral load by patient age. *medRxiv* (2020).
- 3. Valverde, I., et al. Acute Cardiovascular Manifestations in 286 Children with
   Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in
   Europe. Circulation (2020).
- 4. Qiu, H., et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis* 20, 689-696 (2020).
- 5. Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review
   of the proposed mechanisms underlying the age-related difference in severity of
   SARS-CoV-2 infections. *Arch Dis Child* (2020).
- 660 6. Tosif, S., *et al.* Immune responses to SARS-CoV-2 in three children of parents with 661 symptomatic COVID-19. *Nat Commun* **11**, 5703 (2020).
- 662 7. Gorse, G.J., Donovan, M.M. & Patel, G.B. Antibodies to coronaviruses are higher
  663 in older compared with younger adults and binding antibodies are more sensitive
  664 than neutralizing antibodies in identifying coronavirus-associated illnesses. *J Med*665 *Virol* 92, 512-517 (2020).
- 666 8. Freeman, T.L. & Swartz, T.H. Targeting the NLRP3 Inflammasome in Severe 667 COVID-19. *Front Immunol* **11**, 1518 (2020).
- 668 9. Bastard, P., *et al.* Autoantibodies against type I IFNs in patients with life-669 threatening COVID-19. *Science* **370**(2020).
- 67010.Netea, M.G., et al. Trained Immunity: a Tool for Reducing Susceptibility to and the671Severity of SARS-CoV-2 Infection. Cell 181, 969-977 (2020).
- Parri, N., Lenge, M., Buonsenso, D. & Coronavirus Infection in Pediatric
  Emergency Departments Research, G. Children with Covid-19 in Pediatric
  Emergency Departments in Italy. *N Engl J Med* 383, 187-190 (2020).
- Wu, Z. & McGoogan, J.M. Characteristics of and Important Lessons From the
  Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report
  of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239-1242 (2020).
- 67913.Rikhtegaran Tehrani, Z., et al. Performance of nucleocapsid and spike-based680SARS-CoV-2 serologic assays. PLoS One 15, e0237828 (2020).
- Hachim, A., *et al.* ORF8 and ORF3b antibodies are accurate serological markers
  of early and late SARS-CoV-2 infection. *Nat Immunol* 21, 1293-1301 (2020).
- 683 15. Martin-Sancho, L., *et al.* Functional Landscape of SARS-CoV-2 Cellular 684 Restriction. *bioRxiv* (2020).
- Konno, Y., *et al.* SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose
  Activity Is Increased by a Naturally Occurring Elongation Variant. *Cell Rep* 32, 108185 (2020).
- 68817.Yuen, C.K., et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent689interferon antagonists. Emerg Microbes Infect **9**, 1418-1428 (2020).

- Weisberg, S.P., *et al.* Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat Immunol* (2020).
- Schoeman, D. & Fielding, B.C. Is There a Link Between the Pathogenic Human
   Coronavirus Envelope Protein and Immunopathology? A Review of the Literature.
   *Front Microbiol* 11, 2086 (2020).
- 695 20. Weisberg, S.P., *et al.* Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat Immunol* **22**, 25-31 (2021).
- 697 21. Monto, A.S., *et al.* Coronavirus Occurrence and Transmission Over 8 Years in the 698 HIVE Cohort of Households in Michigan. *J Infect Dis* **222**, 9-16 (2020).
- 699 22. Shrock, E., *et al.* Viral epitope profiling of COVID-19 patients reveals cross-700 reactivity and correlates of severity. *Science* **370**(2020).
- 70123.Ng, K.W., et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in702humans. Science (2020).
- 24. Edridge, A.W.D., *et al.* Seasonal coronavirus protective immunity is short-lasting.
   Nat Med 26, 1691-1693 (2020).
- Chan, J.F., *et al.* Genomic characterization of the 2019 novel human-pathogenic
   coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.
   *Emerg Microbes Infect* 9, 221-236 (2020).
- 708 26. Haddad Natalie S, N.D.C., Kuruvilla Merin E, Morrison-Porter Andrea, Fabliha 709 Anam, Kevin S Cashman, Richard P Ramonell, Shuya Kyu, Ankur Singh Saini, 710 Monica Cabrera-Mora, Andrew Derrico, David Alter, John D Roback, Michael 711 Horwath, James B O'Keefe, Henry M Wu, An-Kwok Ian Wong, Alexandra W 712 Dretler, Ria Gripaldo, Andrea N Lane, Hao Wu, Saeyun Lee, Mindy Hernandez, 713 Vanessa Engineer, John Varghese, Sang Le, Iñaki Sanz, John L Daiss, F Eun-714 Hyung Lee. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early 715 COVID-19 Infection. *bioRxiv* (2020).
- 71627.Katzelnick, L.C., et al. Antibody-dependent enhancement of severe dengue717disease in humans. Science 358, 929-932 (2017).
- Guthmiller, J.J., Wilson P. C. Remembering seasonal coronaviruses. *Science* 370, 1272-1273 (2020).
- Le Bert, N., *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and
  SARS, and uninfected controls. *Nature* 584, 457-462 (2020).
- 30. Galani, I.E., *et al.* Untuned antiviral immunity in COVID-19 revealed by temporal
   type I/III interferon patterns and flu comparison. *Nat Immunol* (2020).
- 72431.Wang, E.Y., Mao, T., Klein, J. , Dai, Y. , Huck, J. D., Liu, F., Zheng, N. S., Ting725Zhou, Benjamin Israelow, Patrick Wong, Carolina Lucas, Julio Silva, *et al.* Diverse726Functional Autoantibodies in Patients with COVID-19. *MedRXiv* (2020).
- 32. Glowinska-Olszewska, B., et al. Increasing Co-occurrence of Additional Autoimmune Disorders at Diabetes Type 1 Onset Among Children and Adolescents Diagnosed in Years 2010-2018-Single-Center Study. Front Endocrinol (Lausanne) 11, 476 (2020).
- 731 33. Rodda, L.B., *et al.* Functional SARS-CoV-2-Specific Immune Memory Persists
   732 after Mild COVID-19. *Cell* (2020).
- Young, B.E., *et al.* Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. *Lancet* 396, 603-611 (2020).

- 35. Lam, J.Y., *et al.* Loss of orf3b in the circulating SARS-CoV-2 strains. *Emerg* Microbes Infect, 1-678 (2020).
- Wu, F., et al. A new coronavirus associated with human respiratory disease in
  China. *Nature* 579, 265-269 (2020).
- Burbelo, P.D., Ching, K.H., Klimavicz, C.M. & ladarola, M.J. Antibody profiling by
  Luciferase Immunoprecipitation Systems (LIPS). *J Vis Exp (JoVE)* 32(2009).
- 742 38. Roweis, S. EM Algorithms for PCA and Sensible PCA. (1997).
- 39. Stacklies W., Redestig H., Scholz M., Walther D. & J., S. Methods a
  Bioconductor package providing PCA methods for incomplete data.
- 745 (Bioinformatics, 2007).
- 746 https://bioconductor.org/packages/release/bioc/html/pcaMethods.html.
- 74740.Lê, S., Josse, J. & Husson, F. FactoMineR: An R Package for Multivariate748Analysis. (2008). http://www.jstatsoft.org/v25/i01/
- 749 41. R project. https://cran.rproject.org/web/packages/factoextra/index.html

# Table 1. Subject cohorts details

		Pediatric COVID-19		Adults COVID-19		Negative	
		N (%)		N (%)		N (%)	
Patients	Samples	254		36		33	
	Individuals	122		36		33	
Symptoms	Asymptomatic	44 (36%)		9 (25%)		-	
	Mild/Severe	78/0		25/1		-	
IRxiv preprint doi: https://doi.org/10.110 which was not certified by peer reviev It is ma Age		Mean±stdev	$10.8 \pm 4.9$	Mean±stdev	34 ± 17.1	Mean±stdev	$29.3 \pm 16.3$
		w) is the author/fu de availaເຄືອາເຈົກde	nder, who has r a400(-33/%4)C-	ranted medRxiv ND 4 <b>10 equan</b> ation	a license to di Ial license .	spla <b>x the p</b> reprii (N=13)	nt in perpetuity 30 - 65
		8-12 years	33 (27%)	Min	18	Pediatrics (N=20)	11 - 18
		12-18 years	44 (36%)	Max	71		
Gender	Female	49 (40%)		10 (28%)		17 (51%)	
Genuer	Male	73 (60%)		26 (72%)		16 (49%)	




Figure 1.





Figure 2.



Structural proteins

Non-structural proteins




Figure 4.

Structural proteins

а

b

# Non-structural proteins

15000-

10000-

5000-

0

20000-

15000-

10000-

5000-

d<14

D>14

D>14

d<14

ORF6 LIPS (LU)

ORF10 LIPS (LU)

D>14




Figure 5.

